Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bio Key International Q3 2026 Results: Net Loss of $886K, Loss Narrows

BIO-key International reported total revenues of $5.5M for the nine months ended September 30, 2026, an increase from $4.9M in the prior year period, driven by higher license fees. Despite the revenue growth, the company incurred a net loss available to common stockholders of $6.2M, significantly impacted by a $4.5M deemed dividend related to a warrant inducement.

Watch the Bio Key International Inc earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.51.5
Gross profit1.31.2
Profit before tax-0.9-1.0
Net income-0.9-1.0
EPS (diluted, $ a share)$-4.01$-1.44

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-4.3%
Gross margin90.3%
Operating margin-55.3%
Source

10-Q filed with the SEC, NASDAQ: BKYI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bio Key International Inc: key numbers

Share price
$2.09Close, Nov 16
Market cap
$4.25M
Shares outstanding
2.04MLatest SEC cover page
Sector
Technology
Industry
Services-Prepackaged SoftwareSIC 7372

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bio Key International Inc

All →
8:31 AM ET 8-K
Financial Results

Bio Key International Financial Results

BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.

Term
Q3 2026

“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”

Mike DePasquale, CEO

“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”

Mike DePasquale, CEO
5:07 PM ET 8-K
Shareholder Meeting

Bio Key International Shareholder Meeting

BIO-key International reported the final voting results from its 2026 Annual Meeting of Stockholders, which concluded on October 30, 2026. Stockholders approved Proposal 4, authorizing the issuance of up to 1,236,668 shares of common stock upon the exercise of warrants from an August 2026 inducement transaction to comply with Nasdaq Listing Rule 5635(d).

4:48 PM ET 8-K
Shareholder Meeting

Bio Key International Shareholder Meeting

BIO-key International held its reconvened 2026 Annual Meeting of Stockholders on October 2, 2026, where shareholders elected five directors, ratified M&K CPAs, PLLC as auditors, and approved executive compensation on an advisory basis. The meeting was further adjourned until October 30, 2026, to allow more time for stockholders to vote on Proposal 4 regarding the issuance of common stock upon the exercise of warrants.

5:03 PM ET 8-K
Loan & Debt

Bio Key International Debt Financing Update with Streeterville Capital, LLC

BIO-key International entered into exchange agreements with Streeterville Capital to settle the remaining $416,315.80 balance of a 2025 secured promissory note. The company partitioned the debt into four new notes and immediately exchanged them for 247,805 shares of common stock. As a result of these transactions, the original note has been paid in full.

Counterparty
Streeterville Capital, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.